Adequacy of Antimicrobial Treatment and Outcome of *Staphylococcus aureus* Bacteremia in 9 Western European Countries

Heidi Ammerlaan, Harald Seifert, Stephan Harbarth, Christian Brun-Buisson, Antoni Torres, Massimo Antonelli, Jan Kluytmans, and Marc Bonten, on behalf of the Study on European Practices of Infections with *Staphylococcus aureus* (SEPIA) Study Group

1Department of Medical Microbiology and 2Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, 3Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, and 4Department of Medical Microbiology and Infectious Diseases, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; 5Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; 6Infection Control Program, Geneva University Hospitals and Medical School, Geneva, Switzerland; 7Medical Intensive Care Unit, University of Paris, Hospital Henri Mondor, Paris, France; 8Cap de Servei de Pneumología i Al·lergia Respiratòria, Institut Clínic del Tórax, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Ciber de Enfermedades Respiratorias, University of Barcelona, Barcelona, Spain; and 9Department of Intensive Care and Anesthesiology, Università Cattolica del Sacro Cuore, Rome, Italy

Background. Little is known about the incidence of inadequate treatment of severe *Staphylococcus aureus* infection in Europe. We aimed to evaluate the adequacy of antibiotic therapy for *S. aureus* bacteremia (SAB), to identify determinants of inadequate treatment, and to determine the effect of inadequate treatment on patient outcome in a representative selection of hospitals in 9 Western European countries.

Methods. In this retrospective cohort study, all adult patients with SAB (due to methicillin-susceptible *S. aureus* [MSSA] or methicillin-resistant *S. aureus* [MRSA]) who were admitted to 60 randomly selected hospitals from 1 November 2007 through 31 December 2007 were included. Adequate antimicrobial therapy was defined as intravenous administration of at least 1 antibiotic to which the isolate showed in vitro susceptibility that was initiated within 2 days after onset of SAB.

Results. A total of 334 SAB episodes (257 due to MSSA and 77 due to MRSA) were included. Ninety-four patients (28%) received inadequate empirical therapy (21% in the MSSA group and 52% in the MRSA group). Both length of stay before SAB onset and methicillin-resistant infection were associated with inadequate therapy, with adjusted odds ratios (ORs) of 1.01 (95% confidence interval [CI], 1.00–1.03) and 3.7 (95% CI, 2.2–6.4), respectively. Age (OR, 1.06; 95% CI, 1.03–1.10), Charlson comorbidity score (OR, 2.1; 95% CI, 1.2–3.6), severe sepsis or septic shock (OR, 2.7; 95% CI, 1.5–4.8), and intensive care unit stay at onset of SAB (OR, 2.9; 95% CI, 1.5–5.6) but not inadequate treatment (OR, 0.7; 95% CI, 0.4–1.3) were associated with increased 30-day mortality.

Conclusion. Inadequate empirical antimicrobial therapy for SAB is common in Western Europe and is strongly associated with infection caused by MRSA. In this study, inadequate treatment was not associated with increased 30-day mortality rates.

*Staphylococcus aureus* is responsible for 10%–18% of all community-acquired and ~20% of all nosocomial bacteremias [1, 2], thereby representing a significant burden on health care services [3]. Incidences of both community-acquired and nosocomial *S. aureus* bacteremia (SAB) have increased during recent decades, probably because of an increasing population at risk [4–6]. In addition, methicillin-resistant *S. aureus* (MRSA) has become endemic in the hospitals of most European countries, which may also add to the total burden of SAB [7]. Reported crude hospital mortality rates among adult patients with SAB have ranged from 18% to 46% [2, 8, 9]. Increased mortality rates have been associated with a respiratory source of SAB or unknown primary infection, presence of shock, older age, male sex, and severity of underlying disease [10–13]. Increasing incidences of MRSA infection confront physicians with
increasing difficulties in empirical treatment decisions [14]. The consequences of inadequate therapy include longer hospital stay, higher health care–associated costs, and even higher mortality rates [15–19], although this last association has not been found in some recent studies [20–22].

Little is known about the incidence of and outcomes associated with inadequate treatment of severe S. aureus infection in Western Europe. Our primary aim was, therefore, to determine the occurrence of inadequate empirical treatment among hospitalized patients with SAB in a representative sample of hospitals in 9 Western European countries. Secondary objectives were to determine associations between hospital-specific, patient-specific, and microorganism-specific characteristics and inadequate treatment of SAB and 30-day mortality rates.

**MATERIALS AND METHODS**

**Study design, study setting, and study population.** We performed a retrospective cohort study of patients with microbiologically confirmed SAB from 1 November 2007 through 31 December 2007 with in-hospital follow-up of 30 days. A randomized sample frame was created from a complete list of general and teaching hospitals in Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland, and the United Kingdom. The hospitals were approached in consecutive order of the sample frame. Hospitals were deemed to be ineligible if they had had no SAB episodes during the surveillance period, were a pediatric or psychiatric hospital, or had <50 beds.

Eligible patients were those ≥18 years of age who were hospitalized with SAB in any of the randomly selected hospitals (community-acquired SAB) or who acquired SAB during hospitalization (hospital-acquired SAB) during the study period. The following patients were excluded: those with SAB as part of a polymicrobial bacteremia, those in whom the antimicrobial susceptibility pattern (methicillin-susceptible S. aureus [MSSA] or MRSA) of S. aureus was unknown, those already receiving adequate antimicrobial therapy before the index blood culture was obtained, and those who died within 1 day after the index blood culture was obtained. Identification of S. aureus and determination of antibiotic susceptibilities were performed according to local guidelines and procedures.

Institutional review boards of participating hospitals were informed if deemed necessary by the local investigator. In most hospitals, a formal protocol review was not required, because the study did not influence standard care, and because data collection was completely anonymous. The Danish Data Protection Agency approved participation of Danish hospitals.

**Data collection and variables of interest.** Empirical therapy was defined as all antimicrobial agents administered between the time that the index blood culture was obtained and the receipt of the final blood culture result (ie, identification of S. aureus and its antimicrobial susceptibility pattern) (Table 1). Definitive therapy was defined as all antibiotic therapy administered subsequent to the receipt of final blood culture results [23]. To be categorized as adequate empirical treatment, antimicrobial therapy had to meet the following criteria: intravenous administration of at least 1 antibiotic to which the isolate expressed in vitro susceptibility that started within 2 days after the positive index blood culture had been obtained or within 1 day if the patient had severe sepsis or septic shock. On the basis of severity of illness and primary site of infection, in some cases oral therapy was also considered adequate empirical therapy. These cases were judged by 6 of the investigators (H.S., S.H., C.B.-B., A.T., J.K., and M.B.), and consensus was reached after discussion. To be categorized as adequate definitive treatment, antimicrobial therapy had to meet the following criteria: intravenous administration for at least 3 days (with few exceptions made by the investigators) of at least 1 antibiotic.
Table 2. Results of Hospital Recruitment per Country

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of Hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This table is available in its entirety in the online version of Clinical Infectious Diseases.

to which the isolate expressed in vitro susceptibility for a total duration of at least 14 days and, if empirical treatment was inadequate, adjustment of treatment on the day of the final blood culture result [23, 24]. No antibiotic therapy or monotherapy with aminoglycosides, trimethoprim, fusidic acid, or rifampicin was deemed inadequate.

For all patients in the cohort, the following covariates were considered: MRSA prevalence among SAB episodes in the country based on European surveillance data recorded in the European Antimicrobial Resistance Surveillance System (EARSS) network [7] dichotomized as high (>10%) versus low (≤10%), teaching or nonteaching hospital, age, sex, modified Charlson comorbidity score [25], immunodeficiency status (presence of human immunodeficiency virus or AIDS, splenectomy, immunosuppressive treatment, chemotherapy of <4 weeks duration for SAB, and solid organ or bone marrow transplantation), history of documented colonization or infection due to S. aureus within the previous 12 months, number of hospital days before the index blood culture was obtained (if a patient was transferred from another hospital, the date of admission to the first hospital was used), department at time that the index blood culture was obtained (dichotomized as intensive care unit [ICU] vs. non-ICU), methicillin susceptibility status of the S. aureus isolate, source of SAB (hospital or community acquired), primary site of infection (dichotomized as primary vs secondary SAB), and severity of sepsis (severe sepsis or septic shock vs sepsis [26]).

Mortality was defined as in-hospital death due to any cause within 30 days after the index blood culture was obtained. Whether an end-of-life decision had been made was also recorded.

To validate the quality of study data, we performed a validity check for the recorded data in a sample of 10% of case report forms (CRFs) in 2 randomly chosen participating hospitals per country. The validity check consisted of 2 quality indicators: first, we checked whether all consecutive eligible patients with SAB during the surveillance period were included. In a face-to-face interview, it was determined whether the number of complete CRFs agreed with a provided list of all patients with SAB and whether patients were correctly included or excluded. The inclusion percentage was derived from the number of included patients divided by the number of eligible patients. The second quality indicator was the accuracy of data reporting on treatment. To assess the accuracy of the collected CRFs compared with the “gold standard” medical record, we established the proportion of unknown or inappropriate data in the CRFs for the following selected variables: date of obtaining the index blood culture, date of definitive culture result, oxacillin susceptibility of S. aureus, starting date of first treatment, antibiotic(s) used as first treatment, administration of second treatment within 30 days after index blood culture (and if so, the starting date of second treatment and antibiotic(s) used as second treatment), and outcome 30 days after the index blood culture was obtained. We randomly selected 1, 2, or 3 CRFs per selected hospital. The percentage of correctly recorded answers was derived from the number of correctly recorded items divided by total number of checked items.

Statistical analysis. The primary goal of this study was independent of a specific statistical hypothesis and did not require a sample size calculation. However, to be able to answer the secondary research question (predictors of inadequate treatment), we aimed to include 400 SAB episodes, assuming 25% inadequate treatment and a final model containing 10 variables of significant importance.

Bivariate analyses were performed using Fisher’s exact tests, and Mann-Whitney U tests were performed to compare continuous variables. To analyze adequate treatment and 30-day...
mortality rates and the different covariates contributing, we performed a multivariate logistic regression. Kaplan-Meier survival curves were plotted for patients with MSSA versus MRSA SAB and were compared by means of a signed log-rank test with time to adequate treatment as an outcome.

For sensitivity analysis, multilevel logistic regression analysis predicting adequate treatment and 30-day mortality rates was conducted to correct for cluster effects within hospitals and within countries. If results showed no cluster effects, we assumed patient independence and only present data of the multivariate logistic regression models. Moreover, a propensity score was added as an additional covariate to determine whether measured differences between the inadequate and adequate groups contributed to residual confounding. To calculate a propensity score for the probability of inadequate treatment, we used the multivariate logistic regression model with inadequate treatment as the dependent variable.

We used the Akaike information criterion to determine the model with the best fit of the data (ie, the model with the lowest Akaike information criterion value). Effect modification was examined by using clinically important interaction terms. Various covariates at the hospital and patient levels were screened for colinearity, and in some cases, decisions were made to exclude variables from the model.

Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). For interpretation of the final model results, tests of significance were 2-tailed, and \( P \leq .05 \) was considered to be statistically significant. The data were analyzed using SPSS statistical software, version 15.0 (SPSS), and R, version 2.8.0 (R Foundation for Statistical Computing).

## RESULTS

### Recruitment of hospitals.

For each country, a randomly generated list of hospitals was created. In total, the 9 lists included 5291 hospitals, of which 1007 (19%) were contacted in consecutive order. Of these, 282 (28%) were deemed to be ineligible. Of the remaining 725 hospitals, 100 (14%) consented to participate, whereas 253 (35%) did not respond to the invitation, and 366 (50%) declined to participate (Figure 1; Table 2). Of the 100 hospitals that agreed to participate, 40 (40%) dropped out during the process of data collection.

The proportions of MRSA among SAB episodes per country in the final cohort of 60 hospitals accurately matched the EARSS data [7]; the only significant difference was found for Germany, which had an incidence of MRSA of 38% in our data versus 20% in the EARSS dataset. Furthermore, the balance between teaching and nonteaching hospitals in the complete list of hospitals was comparable for 6 countries. For Switzerland, Denmark, and France, teaching hospitals were overrepresented in our cohort compared with the hospital lists (50% vs 7%, 33% vs 2%, and 67% vs 4% for Switzerland, Denmark, and France, respectively). Figure 2 shows the location and characteristics of the participating hospitals.

### Patient characteristics.

The final cohort consisted of 334 episodes of SAB: 77 (23%) were caused by MRSA, 257 (77%) were caused by MSSA, 158 (47%) were hospital acquired (with
Table 4. Overview of Episodes of Inadequate Empirical Antimicrobial Therapy

<table>
<thead>
<tr>
<th>Variable</th>
<th>MSSA (n = 257)</th>
<th>MRSA (n = 77)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receipt of inadequate treatment</td>
<td>54&lt;sup&gt;a&lt;/sup&gt;</td>
<td>40&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Receipt of antibiotic treatment to which the pathogen was not susceptible</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>11</td>
<td>24</td>
</tr>
<tr>
<td>No treatment</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Penicillin</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Trimethoprim monotherapy</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Oxacillin, penicillin, and gentamicin</td>
<td>...</td>
<td>1</td>
</tr>
<tr>
<td>Other β-lactams</td>
<td>...</td>
<td>12&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Other β-lactam (piperacillin–tazobactam) and antibiotic resistance (ciprofloxacin)</td>
<td>...</td>
<td>2</td>
</tr>
<tr>
<td>Other β-lactam (piperacillin–tazobactam) and amikacin</td>
<td>...</td>
<td>1</td>
</tr>
<tr>
<td>Intermediate resistance to antibiotic</td>
<td>...</td>
<td>3&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Antibiotic resistance (ciprofloxacin)</td>
<td>...</td>
<td>1</td>
</tr>
<tr>
<td>Inadequate route of administration&lt;sup&gt;d&lt;/sup&gt;</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>Antibiotic treatment started ≥2 days (≥1 day for patients with severe sepsis or septic shock) after index blood culture</td>
<td>34</td>
<td>19</td>
</tr>
</tbody>
</table>

NOTE. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.<br><sup>a</sup> The total number of patients who received inadequate treatment is lower than the sum of the separate criteria, because some patients received inadequate treatment according to >1 criterion.<br><sup>b</sup> Four patients received amoxicillin–clavulanic acid, 1 received cefazolin, 3 received ceftriaxone, 1 received cefuroxime, 1 received ertapenem, and 2 received piperacillin–tazobactam.<br><sup>c</sup> Two patients received teicoplanin, and 1 received vancomycin.<br><sup>d</sup> Oral prescription of empirical antibiotics was deemed to be inadequate (with few exceptions, depending on severity of illness and primary site of infection, on the basis of the opinion of the investigators).

Table 5. Overview of Episodes of Inadequate Definitive Antimicrobial Therapy

This table is available in its entirety in the online version of *Clinical Infectious Diseases*
Figure 3. Kaplan-Meier curve with time to adequate antibiotic treatment in patients with *Staphylococcus aureus* bacteremia (SAB). Dotted line, methicillin-resistant *S. aureus* (MRSA) bacteremias; solid line, methicillin-susceptible *S. aureus* (MSSA) bacteremias; plus sign, censored cases (discharged from the hospital). The cumulative incidence of adequate antibiotic treatment over time was significantly lower among patients with MRSA-related SAB (*P* < .001).

Together with length of stay (in days) before SAB (OR, 1.02; 95% CI, 1.00–1.03).

**Effect of inadequate empirical antimicrobial therapy on 30-day mortality rates.** The 30-day mortality rate was 21.3% (20 of 94 patients died) for patients receiving inadequate and 25.0% (60 of 240 patients died) for those receiving adequate empirical therapy within the first 2 days after onset of bacteremia. In bivariate analysis, adequate empirical antimicrobial therapy was not significantly associated with 30-day mortality (OR, 0.69; 95% CI, 0.36–1.33) (Table 6). Covariates that were associated with 30-day mortality in multivariate logistic regression were age, modified Charlson comorbidity score, the severity of illness (defined by severe sepsis or septic shock), and ICU admission at time of onset of SAB. The interaction term between age and modified Charlson comorbidity score was significant and thus retained in the final model. Both inadequate empirical antimicrobial therapy and the presence of MRSA were not significantly associated with 30-day mortality. To adjust for clustering effects and residual confounding due to differences between the group that received adequate treatment and the group that received inadequate treatment, multilevel analysis and a propensity score were added to the final regression model, respectively. Both did not substantially change the effect estimates of the models (data not shown).

**Validation of data quality.** Eighteen (30%) of 60 participating hospitals were randomly assigned to the quality check of data. In these 18 hospitals, 118 of 122 eligible SAB episodes had been included (97%). Thirty-eight of the completed 334 CRFs were randomly selected to compare 9 items with the original patient records. In total, 282 (94%) of 300 items were in accordance with the patient records. No statistically significant differences were found in outcomes between the sampled cases and the total database.

**DISCUSSION**

In this study of 334 episodes of SAB in 9 Western European countries, 28% of patients initially received inadequate antimicrobial therapy, including 21% with MSSA bacteremia and 52% with MRSA bacteremia (even those with a severe clinical status). Five days after the index blood culture was obtained, 92% and 83% of patients received adequate treatment for MSSA
The obvious intuitive association between inadequate treatment and mortality may be
obscured by several factors. First, evidence exists that certain β-lactam antibiotics, although assumed to be inadequate, have some effect in treating MRSA bacteremia [27]. This could explain why 7 (9%) of 77 patients with MRSA bacteremia continued to receive β-lactam antibiotics to which the isolate expressed in vitro resistance, even after recognition of MRSA in the blood culture results. Final results could have been overlooked; possibly, these patients had experienced clinical improvement while receiving so-called inadequate treatment, which is supported by the low 30-day mortality rate (11%) in this subset. Second, although glycopeptides are considered to be adequate for the treatment of MSSA bacteremia, there is evidence that vancomycin is inferior to β-lactam antibiotics for serious MSSA infections [28]. In our study, 13 of 257 MSSA bacteremia episodes were treated with glycopeptide monotherapy, but the 30-day mortality rate in this subset was 15%. Considering glycopeptide monotherapy as inadequate, therefore, would not have changed our interpretations. Third, we adjusted for multiple covariates by using multivariable regression and propensity scoring, but there is still a possibility that residual confounding by indication and confounding by other than antibiotic interventions (eg, foreign body removal and drainage of foci of infection) were insufficiently addressed. Finally, 50% of our patients had community-acquired SAB. Because the true onset of SAB is less obvious in this population, initial adequacy of antimicrobial therapy may have less impact on patient outcome.

Our study also has several limitations. First, we did not perform an external validation of the microbiology data: identifying associations between inadequate treatment and mortality may be more difficult than the obvious intuitive association between inadequate treatment and mortality. The obvious intuitive association between inadequate treatment and mortality may be obscured by several factors. First, evidence exists that certain β-lactam antibiotics, although assumed to be inadequate, have some effect in treating MRSA bacteremia [27]. This could explain why 7 (9%) of 77 patients with MRSA bacteremia continued to receive β-lactam antibiotics to which the isolate expressed in vitro resistance, even after recognition of MRSA in the blood culture results. Final results could have been overlooked; possibly, these patients had experienced clinical improvement while receiving so-called inadequate treatment, which is supported by the low 30-day mortality rate (11%) in this subset. Second, although glycopeptides are considered to be adequate for the treatment of MSSA bacteremia, there is evidence that vancomycin is inferior to β-lactam antibiotics for serious MSSA infections [28]. In our study, 13 of 257 MSSA bacteremia episodes were treated with glycopeptide monotherapy, but the 30-day mortality rate in this subset was 15%. Considering glycopeptide monotherapy as inadequate, therefore, would not have changed our interpretations. Third, we adjusted for multiple covariates by using multivariable regression and propensity scoring, but there is still a possibility that residual confounding by indication and confounding by other than antibiotic interventions (eg, foreign body removal and drainage of foci of infection) were insufficiently addressed. Finally, 50% of our patients had community-acquired SAB. Because the true onset of SAB is less obvious in this population, initial adequacy of antimicrobial therapy may have less impact on patient outcome. Restricting our analyses to hospital-acquired SAB episodes, though, did not change our findings.

Our study also has several limitations. First, we did not perform an external validation of the microbiology data: identifying...
cation of S. aureus and determination of antibiotic susceptibilities were performed according to local protocols. Second, 30-day mortality was assessed in the hospital setting only, and deaths occurring after hospital discharge (but still within 30 days after the index blood culture was obtained) were not included. Thus, informative censoring could have biased our effect estimates. However, all patients (except for 1 patient with an end-of-life decision) who were discharged from the hospital within 30 days were categorized as having resolved SAB according to the physicians’ opinion, and 31 of 36 patients with an end-of-life decision died during hospitalization. Of the remaining 5 patients (all of whom had unresolved SAB), only 1 was discharged within 30 days. This suggests that patients who were discharged before 30 days after the index blood culture had a good prognosis and that it is unlikely that incomplete follow-up strongly biased our findings. Third, although susceptibility test results, route and duration of administration, and time to adequate treatment were included in the definition of adequate treatment, appropriate dosing of antibiotic treatment, switching to narrow-spectrum antibiotics, and accordance with local antibiotic guidelines were not [23, 24]. With these criteria, rates of inadequate treatment would have been even higher.

**SEPIA STUDY GROUP**

C. Leitz, Skive Sygehus and Viborg Sygehus, Denmark; B. Kristensen, Århus kommunehospital and Århus Amtssygehus, Denmark; L. S. Teglbjærg, Sygehus Fyn Svendborg, Denmark; M. Tvede, Rigshospitalet, Denmark; G. Beraud, Centre Hospitalier Régional Universitaire de Lille, France; C. Pulcini, Centre Hospitalier Universitaire de Nice, France; W. Kern, Universitätsklinikum Freiburg, Freiburg, Germany; S. Schmidt, Bundesklinikum Basel, Switzerland; N. Kuylenstierna, Falu lasarett, Sweden; H. van Dessel, Academisch Ziekenhuis Maastricht, the Netherlands; B. G. Moffie, Vlietland Ziekenhuis, the Netherlands; B. U. Ridwan, Westfrisegasthuis, Hoorn, the Netherlands; C. P. Timmerman, Tergooiziekenhuizen, the Netherlands; J. M. van Duin, Ruwaard van Putten Ziekenhuis, Netherlands; J. M. van Duin, Ruwaard van Putten Ziekenhuis, Netherlands; X. Beristain, Virgen del Camino, Pamplona, Spain; A. Bethes, Hospital de Sant Pau, Barcelona, Spain; A. Campos, Complejo Asistencial de Soria, Spain; A. Canut Blasco, Santiago Apostol, Vitoria-Gasteiz, Spain; A. Chinchilla, Virgen de los Lirios, Alcoy, Spain; B. Jacobsson, Lindesbergs lasaret, Sweden; A. Hammarlund, Angelholms sjukhus, Sweden; B. Hill, Sundsvalls sjukhus, Sweden; N. Kuylenstierna, Falu lasaret, Sweden; H. Montelius, Blekingesjukhuset i Karlskrona, Sweden; S. Stenmark, Norrlands Universitetssjukhus Umeå, Sweden; L. Blättler, Universitätssspital Basel, Switzerland; N. Boillat, Institut Central des Hôpitaux Vaudois, Switzerland; T. Bregenzer, Kantonsspital Aarau, Switzerland; C. Chapuis-Taillard, Centre hospitalier universitaire Vaudois Lausanne, Switzerland; N. Denison, Hôpital de la Tour, Meyrin, Switzerland; V. Erard, Centre hospitalier universitaire Vaudois Lausanne, Switzerland; U. Flickiger, Universitätssspital Basel, Switzerland; D. Genné, Hôpital de La Chaux-de-Fonds, Switzerland; S. Keller, Kantonsspital Aarau, Switzerland; R. Lienhard, Hôpital de La Chaux-de-Fonds, Switzerland; N. Troillet, Institut Central des Hôpitaux Vaudois, Switzerland; D. Weiss, Spital Thun, Switzerland; R. Brindle, Portsmouth Hospitals, United Kingdom; B. Faris, Trafford Healthcare National Health Service (NHS) Trust, United Kingdom; M. P. A. Lessing, Heatherwood and Wexham Park Hospitals NHS Foundation Trust, Slough, United Kingdom; O. M. Williams, Regional Health Protection Agency Laboratory, Bristol Royal Infirmary, United Kingdom.

**Acknowledgments**

We thank Genacris and, in particular, H. Strongman, for assisting in data acquisition.

**Financial support.** Novartis. The funder played no role in study design, collection, analysis, and interpretation of data, writing of the report, or the decision to submit the article for publication.

**Potential conflicts of interest.** H.A. has received speaking fees from Novartis. H.S. has received research grants from Basilea and Bayer, has received speaking fees from Bayer, Gilead, Novartis, O xo id, Pfizer, and Wyeth, and is a member of the advisory board of Johnson and Johnson and Novartis Germany. S.H. has received consulting fees from 3M and Roche, is a member of the speakers’ bureau for Biomerieux, and is a member of the advisory board of Destiny Pharma. A.T. has received honoraria from MSD Spain, Novartis, Wyeth, and Bayer and has received a research grant from Pfizer. J.K. has received consulting fees from 3M, Novabav, and Wyeth, has received speaking fees from 3M and Becton Dickenson, is a member of the speakers’ bureau for Biomerieux, and is a member of the advisory board of Destiny Pharma. M.B. has received research funding from Novartis and 3M, is a member of the speakers’ bureau for Pfizer, and is a member of the advisory board of 3M and Novartis. All other authors: no conflicts.

**References**


